Repository logo
 

Sigma1 receptors inhibit store-operated Ca2+ entry by attenuating coupling of STIM1 to Orai1.

Accepted version
Peer-reviewed

Repository DOI


Type

Article

Change log

Authors

Srivats, Shyam 
Balasuriya, Dilshan 
Pasche, Mathias 
Vistal, Gerard 
Edwardson, J Michael 

Abstract

Sigma1 receptors (σ1Rs) are expressed widely; they bind diverse ligands, including psychotropic drugs and steroids, regulate many ion channels, and are implicated in cancer and addiction. It is not known how σ1Rs exert such varied effects. We demonstrate that σ1Rs inhibit store-operated Ca(2+)entry (SOCE), a major Ca(2+)influx pathway, and reduce the Ca(2+)content of the intracellular stores. SOCE was inhibited by expression of σ1R or an agonist of σ1R and enhanced by loss of σ1R or an antagonist. Within the endoplasmic reticulum (ER), σ1R associated with STIM1, the ER Ca(2+)sensor that regulates SOCE. This interaction was modulated by σ1R ligands. After depletion of Ca(2+)stores, σ1R accompanied STIM1 to ER-plasma membrane (PM) junctions where STIM1 stimulated opening of the Ca(2+)channel, Orai1. The association of STIM1 with σ1R slowed the recruitment of STIM1 to ER-PM junctions and reduced binding of STIM1 to PM Orai1. We conclude that σ1R attenuates STIM1 coupling to Orai1 and thereby inhibits SOCE.

Description

Keywords

Calcium, Calcium Channels, Calcium Signaling, Cell Line, Cell Line, Tumor, Cell Membrane, Endoplasmic Reticulum, HEK293 Cells, HeLa Cells, Humans, Membrane Proteins, Neoplasm Proteins, ORAI1 Protein, Receptors, sigma, Stromal Interaction Molecule 1, Sigma-1 Receptor

Journal Title

J Cell Biol

Conference Name

Journal ISSN

0021-9525
1540-8140

Volume Title

Publisher

Rockefeller University Press
Sponsorship
Biotechnology and Biological Sciences Research Council (BB/J018236/1)
Biotechnology and Biological Sciences Research Council (BB/F001320/1)
Biotechnology and Biological Sciences Research Council (BB/L000075/1)
Wellcome Trust (101844/Z/13/Z)
We thank T.P. Su (National Institutes of Health, USA) for σ1R siRNA and control plasmids, S. Srikanth and Y. Gwack (University of Los Angeles California, USA) for the Orai1E106Q 28 construct, A. Parekh (University of Oxford, UK) for the GFP-NFAT plasmid, P. Hogan (La Jolla Institute for Allergy and Immunology, USA) for the CAD construct and D. M. F. Cooper (University of Cambridge, UK) for the Orai1-CFP construct. S.S. is supported by the Cambridge International and European Trust, D.B. by a David James Bursary from the Department of Pharmacology, Cambridge, and G.V. by the Jardines Matheson student bursary. This work was supported by grants from the Biotechnology and Biological Sciences Research Council (BB/J018236/1 to J.M.E and BB/F001320/1 to R.D.M.L.), and the Wellcome Trust (101844 to C.W.T). The authors declare no competing financial interests.